Latest news with #JohnHanna
Forbes
29-05-2025
- Business
- Forbes
Corporate Mentions Of ‘DEI' Dropped 72% In 2025, Analysis Finds
References to diversity, equity and inclusion in Fortune 100 company reports dropped 72% between 2024 and 2025, according to an analysis by Gravity Research, as pressure from the Trump administration has led corporations to gut their diversity initiatives. Corporations have faced anti-DEI pressure from the government and conservative activists. (AP ... More Photo/John Hanna, File) Usage of the acronym 'DEI' in Fortune 100 company reports had the steepest decline between 2024 and 2025, decreasing by 98%, while each individual term also declined significantly: Mentions of 'diversity' dropped 62%, 'equity' decreased 48% and 'inclusion' declined 43%. Gravity Research, a firm that studies how companies manage their reputations and respond to social pressures, analyzed more than 1,300 financial filings, proxy statements, earnings calls and other documents filed between 2023 and 2025. References to DEI also decreased between 2023 and 2024, though to a lesser degree: 'DEI' declined 26% between those years, while mentions of 'diversity' dropped 30%. Words explicitly referring to diversity, including 'DEI' and 'racial diversity,' declined 72% overall between 2024 and 2025, while words Gravity Research considered to be more neutral, like 'inclusion' and 'belonging,' declined 34% overall. Gravity Research found companies adopted more 'neutral' language in 2024 as a potentially less controversial alternative to DEI, but had largely abandoned these terms by 2025 amid pressure from the federal government. Use of the word 'belonging' increased 87% between 2023 and 2024 as a 'safer' alternative to DEI, but mentions of 'belonging' decreased 47% between 2024 and 2025. Mentions of employee resource groups, which are often centered around racial or gender groups and were a frequent casualty of the corporate push away from DEI, dropped between 2024 and 2025, and many of these references mention these groups are open to all. Earnings calls were the only place where mentions of 'DEI' increased, rising 390% between 2024 and 2025, as heightened scrutiny over DEI programs led to an increase in media and shareholder inquiries about these initiatives. Joanna Piacenza, vice president of thought leadership at Gravity Research, said the report 'speaks volumes to the current political environment. It's become so charged, it's become so risky for corporations to speak publicly about their DEI commitments, stating companies are 'trying to keep up not only with how polarized things have become, but what they think consumers and other stakeholders want from them.' Many companies have dropped their diversity programs or reframed them to focus more on general 'inclusion' or employee well-being amid pressure from conservative activists and the federal government. Among the first executive orders of President Donald Trump's second term were multiple directives targeting DEI programs across the federal government, which included threats to 'combat illegal private-sector DEI preferences.' Companies like Meta, Amazon and Walmart began dismantling diversity programs before Trump took office, and many more backed off after his inauguration. Many of these companies have abandoned diversity hiring goals, which Trump has framed as illegal discrimination, and some of these companies have cut DEI officer roles or transformed them to focus on general employee development. Anti-DEI activist Robby Starbuck, who has more than 800,000 followers on X, has claimed credit for several of the companies that have watered down their diversity initiatives, including Pepsi, Walmart and McDonald's, by threatening to expose their 'woke' policies on his social media. A Gravity Research survey published last month found two in five companies plan to decrease LGBTQ Pride Month engagement this year, while another two-fifths said their engagement would stay the same and the rest said they had not decided. The survey elicited responses from 49 corporate executives from Fortune 1000 companies, some of whom cited pressure from the Trump administration and conservative activists. Of the companies who said they would pull back support for Pride, 43% of those said they would reduce external-facing engagement, including social media posts and presences at Pride marches. Gravity Research president Luke Hartig told Forbes the survey 'reveals just how dramatically the cultural and political tides have turned,' stating two-fifths of companies scaling back Pride Month engagement 'would've been unthinkable just five years ago.' Several of the nation's largest Pride organizations told Forbes earlier this year some longtime corporate sponsors pulled back funding this year, leaving the organizations in a bind to replace the lost money. San Francisco Pride told Forbes it lost $200,000 in funds after previous sponsors including Comcast and Diageo pulled out, while NYC Pride said a quarter of its sponsors either withheld or reduced funding this year, representing $750,000 in lost funds. 2 In 5 Corporations Scaling Back LGBTQ Pride Engagement Amid Trump Administration Pressure, Survey Finds (Forbes) IBM Reportedly Walks Back Diversity Policies, Citing 'Inherent Tensions': Here Are All The Companies Rolling Back DEI Programs (Forbes) St. Louis Pride Says Anheuser-Busch Ended Sponsorship—As Corporate Support For LGBTQ Pride Celebrations Dwindles (Forbes)
CTV News
18-05-2025
- Business
- CTV News
Cape Breton Eagles seek fifth new head coach in six years
Left to right - Irwin Simon (majority owner, Cape Breton Eagles), Sylvain Couturier (general manager) and John Hanna (assistant general manager) are pictured at a table during a news conference at Sydney's Centre 200.
Yahoo
01-05-2025
- Business
- Yahoo
CareDx Inc (CDNA) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Strategic Investments
Release Date: April 30, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. CareDx Inc (NASDAQ:CDNA) reported a strong first quarter with a revenue increase of 18% year over year, reaching $84.7 million. The company achieved its seventh consecutive quarter of sequential testing volume growth, with testing services revenue up 15% year over year. CareDx Inc (NASDAQ:CDNA) ended the quarter with a robust cash balance of $231 million and no debt, providing financial stability. The company launched two expanded indications for Allosure, enhancing its product offerings for pediatric heart transplant patients and simultaneous pancreas kidney transplant patients. CareDx Inc (NASDAQ:CDNA) made significant strides in market access, adding 3.5 million new covered lives for Allomap PAP and 15.5 million for Allosure testing. Operating expenses increased, driven by investments in sales and marketing, which may impact profitability if not managed carefully. The company faced a $1.1 million write-off for aged receivables, indicating potential challenges in collections. CareDx Inc (NASDAQ:CDNA) is involved in a securities class action litigation, with an anticipated out-of-pocket expense of approximately $5.4 million. There was a muted start to the year in transplant procedures, which could impact future revenue growth if not addressed. The company anticipates a $5 million annual investment for the Epic integration, which could strain resources if not offset by increased efficiencies. Warning! GuruFocus has detected 5 Warning Signs with CDNA. Q: Did you see signs of surveillance volume starting to come back in the quarter, and where are we at in that process? A: John Hanna, CEO: Absolutely, we are seeing signs of that volume coming back. We made progress on surveillance testing protocols in the 4th quarter and in the 1st quarter, and we see surveillance testing and kidney volumes really leading our growth across all organs. Q: How should we be thinking about the rate of spend throughout the rest of the year, given the higher R&D and SGA expenses this quarter? A: Abhishek Jane, CFO: Operating expenses were up 6% year over year, but with revenue growth of 18%, this provides about 600 to 700 basis points improvement in operating expenses as a percent of revenue. The increase is primarily driven by sales and marketing investments, while R&D expenses remain flat. Q: Is the benefit of surveillance volumes getting pulled forward, or is it still expected in the back half of the year? A: John Hanna, CEO: We are not suggesting a pull forward. We anticipated some impact from weather and fires at the beginning of the quarter, but we are making progress on surveillance testing. We expect growth in Q2 as centers reinitiate protocols and gradually increase volumes. Q: What are your thoughts on the potential issuance of new LCDs for transplant testing by the MACs? A: John Hanna, CEO: The data supporting surveillance testing has grown significantly. We saw a press release from the agency in August about potential new LCDs, but we don't have a timeline. We continue to push forward with studies like the KOR study to solidify the position for coverage. Q: Can you discuss the impact of the new CPT code for Allosure and how it leads to greater in-network coverage and higher ASP per test? A: John Hanna, CEO: The new Allosure-specific code allows us to contract with third-party payers and get in-network, which facilitates first-pass claim payments at contracted rates. This should help convert coverage policies into contracts, improving ASPs. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Cision Canada
24-04-2025
- Business
- Cision Canada
HLS Therapeutics to Host Q1 2025 Financial Results Conference Call
TORONTO, April 24, 2025 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q1 2025 financial results on Thursday, May 8, 2025. The Company will hold a conference call that same day at 8:30 a.m. ET to discuss its results. The call will be hosted by Craig Millian, Chief Executive Officer; John Hanna, Chief Financial Officer; and Brian Walsh, Chief Commercial Officer. Slides to accompany management's prepared remarks will be available to view via the webcast. CONFERENCE ID: 41562 DATE: Thursday, May 8, 2025 TIME: 8:30 a.m. ET WEBCAST LINK: TRADITIONAL DIAL-IN NUMBER: 1-888-699-1199 or 1-416-945-7677 RAPIDCONNECT: To instantly join the conference call by phone, please use the following URL to easily register and be connected into the conference call automatically: TAPED REPLAY: 1-888-660-6345 or 1-646-517-4150 REPLAY CODE: 41562# The taped replay will be available for 14 days and the archived webcast will be available for 365 days. A link to the live audio webcast of the conference call will also be available on the events page of the investors section of HLS Therapeutics' website at Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to hear the webcast. ABOUT HLS THERAPEUTICS INC. Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products that address unmet needs in the treatment of psychiatric disorders and cardiovascular disease. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information visit:
